These studies may be confounded by the inclusion of multiple cancer types in the analyses since better responses to anti-PD1 and anti-PDL1 treatments have been reported in females with NSCLC compared to males, however the opposite trend was observed in colorectal cancer (6). This evidence concerns the gene CD274 and cancer.